Vitura Health has signed its first distribution agreement with MedReleaf Australia.
Under the deal, MedReleaf – a wholly owned subsidiary of Canadian firm Aurora Cannabis – will have products listed on Vitura’s Canview platform and distributed through Burleigh Heads Cannabis’ pharmacy network.
Brands available through Canview include IndiMed, Aurora, Whistler, Cannabis Co and CraftPlants.
It is the second major distribution contract signed by MedReleaf Australia in recent months following the agreement struck in December with Leafio.
Vitura predicted the deal could generate revenue of around $15 million over time, depending on demand, product uptake and broader regulatory and market conditions.
Vitura chief executive Ryan Tattle said the partnership will deliver “clear commercial outcomes for both parties”, and include the introduction of new products and formats.
Neurotech International
Neurotech has initiated the first clinical site for its Phase 3 ‘Beyond Harmony’ trial evaluating its cannabinoid-based therapy NTI164 in children with Autism Spectrum Disorder (ASD).
The first site – Monash Children’s Hospital – is now open for patient screening and recruitment following regulatory approvals, with additional sites expected to come online in the coming months.
The multi-centre, randomised, placebo-controlled study will enrol 150 patients and assess the efficacy, safety and tolerability of the therapy, targeting core symptoms of ASD and underlying neuroinflammatory pathways.
Chief executive and managing director Anthony Filippis said the first trial site marked a “major milestone” for the firm, and families affected by ASD.
“Beyond Harmony is designed to rigorously evaluate NTI164 in a well-controlled setting, and we look forward to progressing recruitment across multiple centres,” he said.
Neurotech has previously reported positive early-stage clinical results for NTI164 in autism and PANDAS/PANS.